Pdt Partners, LLC Syros Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

  • $1.02 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$3.26 - $4.66 $313,233 - $447,751
-96,084 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$4.08 - $5.66 $84,525 - $117,258
-20,717 Reduced 17.74%
96,084 $429,000
Q2 2021

Aug 16, 2021
SELL
$5.01 - $7.48 $153,511 - $229,194
-30,641 Reduced 20.78%
116,801 $637,000
Q1 2021

May 17, 2021
BUY
$7.19 - $14.95 $452,229 - $940,310
62,897 Added 74.39%
147,442 $1.1 Million
Q4 2020

Feb 16, 2021
BUY
$6.66 - $14.66 $22,823 - $50,239
3,427 Added 4.22%
84,545 $917,000
Q3 2020

Nov 16, 2020
BUY
$8.69 - $14.47 $397,289 - $661,539
45,718 Added 129.15%
81,118 $717,000
Q2 2020

Aug 14, 2020
BUY
$5.21 - $11.03 $521 - $1,103
100 Added 0.28%
35,400 $377,000
Q1 2020

May 15, 2020
SELL
$4.46 - $9.2 $14,713 - $30,350
-3,299 Reduced 8.55%
35,300 $209,000
Q4 2019

Feb 14, 2020
BUY
$4.52 - $10.1 $101,998 - $227,916
22,566 Added 140.75%
38,599 $267,000
Q3 2019

Nov 14, 2019
SELL
$7.14 - $11.65 $29,752 - $48,545
-4,167 Reduced 20.63%
16,033 $166,000
Q2 2019

Aug 14, 2019
BUY
$5.5 - $9.75 $111,100 - $196,950
20,200 New
20,200 $187,000
Q4 2018

Feb 14, 2019
SELL
$5.55 - $11.34 $287,761 - $587,967
-51,849 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$9.74 - $12.92 $62,092 - $82,365
-6,375 Reduced 10.95%
51,849 $618,000
Q2 2018

Aug 14, 2018
SELL
$10.16 - $13.65 $72,908 - $97,952
-7,176 Reduced 10.97%
58,224 $594,000
Q1 2018

May 15, 2018
BUY
$9.47 - $12.98 $34,044 - $46,663
3,595 Added 5.82%
65,400 $849,000
Q4 2017

Feb 14, 2018
BUY
$8.45 - $17.48 $155,809 - $322,313
18,439 Added 42.52%
61,805 $601,000
Q3 2017

Nov 14, 2017
BUY
$13.52 - $23.75 $586,308 - $1.03 Million
43,366
43,366 $638,000

About Syros Pharmaceuticals, Inc.

SYRS Quotes by TradingView
  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.25M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email